Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis

Journal of Clinical Oncology

Volumn 31, Issue 19, 2013, Pages 2519-2520

  Zelek, Laurent ^a   Laval, Guillemette ^b   Asselain, Bernard ^c  

^a AVICENNE HOSPITAL   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CORTICOSTEROID; OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;

CARCINOMATOUS PERITONITIS; HUMAN; INTESTINE OBSTRUCTION; LETTER; MALIGNANT BOWEL OBSTRUCTION; MEDICAL CARE; PERITONEAL CARCINOMATOSIS; PRIORITY JOURNAL; SCORING SYSTEM; VOMITING; FEMALE; MALE; NOTE; PERITONEUM TUMOR;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INTESTINAL OBSTRUCTION; MALE; PEPTIDES, CYCLIC; PERITONEAL NEOPLASMS; SOMATOSTATIN;

EID: 84883108847     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.4634     Document Type: Letter

References (12)

1. Mariani P, Blumberg J, Landau A, et al: Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 30:4337-4343, 2012
2. Laval G, Rousselot H, Toussaint-Martel S, et al: SALTO: A randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction. Bull Cancer 99:E1-E9, 2012
3. Ripamonti C, Mercadante S, Groff L, et al: Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial. J Pain Symptom Manage 19:23-34, 2000
4. Mercadante S, Ripamonti C, Casuccio A, et al: Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8:188-191, 2000
5. Mystakidou K, Tsilika E, Kalaidopoulou O, et al: Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: A randomized, double-blind, controlled clinical trial. Anticancer Res 22:1187-1192, 2002
6. Mercadante S, Spoldi E, Caraceni A, et al: Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 7:295-299, 1993
7. Mangili G, Franchi M, Mariani A, et al: Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 61:345-348, 1996
8. Khoo D, Hall E, Motson R, et al: Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 30A:28-30, 1994
9. Hisanaga T, Shinjo T, Morita T, et al: Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 40:739-745, 2010
10. Matulonis UA, Seiden MV, Roche M, et al: Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 30:563-569, 2005
11. Myers J, Tamber A, Farhadian M: Management of treatment-related intermittent partial small bowel obstruction: The use of octreotide. J Pain Symptom Manage 39:e1-e3, 2010
12. Shima Y, Ohtsu A, Shirao K, et al: Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol 38:354-359, 2008